Home/Filings/4/0001193125-25-326948
4//SEC Filing

Burrows Francis 4

Accession 0001193125-25-326948

CIK 0001422143other

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 4:30 PM ET

Size

8.9 KB

Accession

0001193125-25-326948

Insider Transaction Report

Form 4
Period: 2025-12-18
Burrows Francis
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-18$4.80/sh+35,000$168,00057,461 total
  • Sale

    Common Stock

    2025-12-18$9.78/sh23,726$231,93133,735 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-12-1835,0000 total
    Exercise: $4.80Exp: 2026-01-29Common stock (35,000 underlying)
Footnotes (4)
  • [F1]Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability.
  • [F2]Includes 857 shares acquired on May 17, 2025 and 899 shares acquired on November 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan.
  • [F3]This transaction was executed in multiple trades at prices ranging from $9.77 to $9.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]This option is fully vested.

Documents

1 file

Issuer

Kura Oncology, Inc.

CIK 0001422143

Entity typeother

Related Parties

1
  • filerCIK 0002051119

Filing Metadata

Form type
4
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 4:30 PM ET
Size
8.9 KB